{"database":"MetabolomicsWorkbench","file_versions":[{"headers":{"Content-Type":["application/json"]},"body":{"files":{"Other":["http://www.metabolomicsworkbench.org/rest/study/study_id/ST002126/mwtab"]},"type":"primary"},"statusCodeValue":200,"statusCode":"OK"}],"scores":null,"additional":{"omics_type":["Metabolomics"],"technology_type":["EI","Mass Spectrometry"],"species":["Mus Musculus"],"full_dataset_link":["http://www.metabolomicsworkbench.org/data/DRCCMetadata.php?Mode=Study&StudyID=ST002126"],"study_factor":["Source_Name[gating]:Lin– Scal1+ c-Kit+ CD48– CD150+ (HSC) | Treatment:NR 8 weeks, 5 FU 2 weeks, [13C, 15N] AAs were incorporated for 24 h and subsequently washed out for 12 h | Batch:1d | Note:[13C, 15N] AA levels and [13C]TCA substrate levels in different time point were calculated for AA catabolism (Fig5.L).","Source_Name[gating]:Lin– Scal1+ c-Kit+ CD48– CD150+ (HSC) | Treatment:HSC Basal or Ctrl, [13C, 15N] AAs were incorporated for 1 h | Batch:1c | Note:[13C, 15N] AAs were used for AA uptake (Fig2.B, Fig5M); unlabeled AAs and TCA substrate were used for total AA levels (Fig2.C, Fig5K) and TCA substrate levels (Fig2.K, Fig5J).","Source_Name[gating]:Lin– Scal1+ c-Kit+ CD48– CD150+ (HSC) | Treatment:5 FU 2 weeks, [13C, 15N] AAs were incorporated for 24 h and subsequently washed out for 6 h | Batch:1d | Note:[13C, 15N] AA levels and [13C]TCA substrate levels in different time point were calculated for AA catabolism (Fig5.L).","Source_Name[gating]:Lin– Scal1+ c-Kit+ CD48– CD150+ (HSC) | Treatment:5 FU 2 weeks, [13C, 15N] AAs were incorporated for 1 h | Batch:1c | Note:[13C, 15N] AAs were used for AA uptake (Fig2.B, Fig5M); unlabeled AAs and TCA substrate were used for total AA levels (Fig2.C, Fig5K) and TCA substrate levels (Fig2.K, Fig5J).","Source_Name[gating]:Lin– Scal1+ c-Kit+ CD48– CD150+ (HSC) | Treatment:NR 8 weeks, 5 FU 2 weeks, [13C, 15N] AAs were incorporated for 24 h and subsequently washed out for 0 h | Batch:1d | Note:[13C, 15N] AA levels and [13C]TCA substrate levels in different time point were calculated for AA catabolism (Fig5.L).","Source_Name[gating]:Lin– Scal1+ c-Kit+ CD48– CD150+ (HSC) | Treatment:HSC Basal or Ctrl, NR-treatment 8 weeks, [13C, 15N] AAs were incorporated for 1 h | Batch:1c | Note:[13C, 15N] AAs were used for AA uptake (Fig5M); unlabeled AAs and TCA substrate were used for total AA levels (Fig2.C, Fig5K) and TCA substrate levels (Fig5J).","Source_Name[gating]:Lin– Scal1+ c-Kit+ CD48– CD150+ (HSC) | Treatment:NR 8 weeks, 5 FU 2 weeks, [13C, 15N] AAs were incorporated for 1 h | Batch:1c | Note:[13C, 15N] AAs were used for AA uptake (Fig5M); unlabeled AAs and TCA substrate were used for total AA levels (Fig2.C, Fig5K) and TCA substrate levels (Fig5J).","Source_Name[gating]:Lin– Scal1+ c-Kit+ CD48– CD150+ (HSC) | Treatment:5 FU 2 weeks, [13C, 15N] AAs were incorporated for 24 h and subsequently washed out for 0 h | Batch:1d | Note:[13C, 15N] AA levels and [13C]TCA substrate levels in different time point were calculated for AA catabolism (Fig5.L).","Source_Name[gating]:Lin– Scal1+ c-Kit+ CD48– CD150+ (HSC) | Treatment:5 FU 2 weeks, [13C, 15N] AAs were incorporated for 24 h and subsequently washed out for 12 h | Batch:1d | Note:[13C, 15N] AA levels and [13C]TCA substrate levels in different time point were calculated for AA catabolism (Fig5.L).","Source_Name[gating]:Lin– Scal1+ c-Kit+ CD48– CD150+ (HSC) | Treatment:NR 8 weeks, 5 FU 2 weeks, [13C, 15N] AAs were incorporated for 24 h and subsequently washed out for 6 h | Batch:1d | Note:[13C, 15N] AA levels and [13C]TCA substrate levels in different time point were calculated for AA catabolism (Fig5.L)."],"submitter_affiliation":["Sun Yat-sen University"],"tissue":["Bone Marrow"],"sample_protocol":["GC POSITIVE ION MODE."],"repository":["MetabolomicsWorkbench"],"metabolite_name":["Proline, 2TBDMS","Tyrosine, 3TBDMS","[13C, 15N]Tyrosine, 3TBDMS","Isoleucine, 2TBDMS","Citrate","[13C]Fumatate","[13C, 15N]Glutamic acid, 3TBDMS","Alanine, 2TBDMS","L-Cysteine, 3TBDMS","[13C]Alpha_Ketoglutarate","[13C, 15N]Isoleucine, 2TBDMS","[13C, 15N]Methionine, 2TBDMS","[13C, 15N]Histidine, 3TBDMS","Glycine, 2TBDMS","[13C, 15N]Valine, 2TBDMS","[13C, 15N]Phenylalanine, 2TBDMS","[13C, 15N]Glycine, 2TBDMS","[13C, 15N]Lysine, 3TBDMS","Threonine, 3TBDMS","Aspartic acid, 3TBDMS","Alpha_Ketoglutarate","[13C, 15N]Leucine, 2TBDMS","Hydroxyproline, (E)-, 3TBDMS","Succinate","Methionine, 2TBDMS","Histidine, 3TBDMS","[13C, 15N]Serine, 3TBDMS","[13C]Malate","[13C, 15N]Alanine, 2TBDMS","[13C, 15N]Aspartic acid, 3TBDMS","Phenylalanine, 2TBDMS","Serine, 3TBDMS","[13C]Succinate","Malate","Glutamic acid, 3TBDMS","Leucine, 2TBDMS","Lysine, 3TBDMS","Fumatate","[13C, 15N]Threonine, 3TBDMS","[13C]Citrate","Valine, 2TBDMS","[13C, 15N]Proline, 2TBDMS","Glutamine, 3TBDMS"],"data_protocol":[""],"name_synonyms":["Amino Acid, Acid, amino acids, Amino acids, Aminokarbonsaeure, Aminosaeure, Aminocarbonsaeure, Amino acid, Cell., Acids, alpha-amino acids, alpha-amino acid, Amino, alpha-amino carboxylic acids"],"sample_synonyms":["iones., Ionen, ion, Ion, ions"],"additional_accession":[]},"is_claimable":false,"name":"Amino acids and TCA substrates in hematopoietic cells (Part3)","description":null,"dates":{"publication":""},"accession":"ST002126","cross_references":{"TAXONOMY":["10090"]}}